Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma
Mark C. de Gooijer, Daria M. Fedorushkova, Ping Zhang, Levi C.M. Buil, Ceren H. Çitirikkaya, Hilal Çolakoğlu, Ana Rita R. Maia, Irena Bočkaj, Margarita Espitia Ballestas, Laura E. Kuil, Jos H. Beijnen, Olaf van Tellingen
This study evaluates the efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma in vitro and in vivo, finding strong in vitro activity but no antitumor effect in mouse models.
Cellular Oncology · Feb 16, 2026Peer-reviewedCancer Biology